(CIDRAP News) In a bird's eye view of pandemic H1N1 seroprevalence studies published so far, the World Health Organization (WHO) said today the reports consistently show older people had partial protection and that infection rates were higher in younger people, but it's too soon to estimate a global attack rate.
(CIDRAP News) Leading public health officials and experts have sharply rejected charges from some European officials that pharmaceutical companies used exaggerated claims about the H1N1 pandemic threat to scare governments into buying unnecessary stockpiles of vaccines.
(CIDRAP News) The World Health Organization (WHO) said today that the fast-tracking of vaccines for pandemic H1N1 influenza won't compromise safety, while acknowledging that clinical data will be limited when the first doses are administered.
The World Health Organization (WHO) reported 331 cases of swine influenza H1N1 in 11 countries as of 6 a.m. GMT today. The case numbers by country are United States, 109 (1 death) (these are yesterday's totals); Mexico, 156 (9 deaths), Canada, 34; Spain, 13; United Kingdom, 8; New Zealand, 3; Germany, 3; Israel, 2; and 1 each in Austria, the Netherlands, and Switzerland. [WHO update 7]
(CIDRAP News) David Nabarro, influenza coordinator for the United Nations (UN), said during a press conference yesterday that the world is better prepared to respond to an influenza pandemic, but he added that continuing outbreaks in some countries are a reminder that a major threat remains.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
Editor's note: This is the second in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.